1	Regarding	_	VBG	_	_	19	ADV	_	_
2	your	_	PRP$	_	_	6	NMOD	_	_
3	Oct.	_	NNP	_	_	6	NMOD	_	_
4	4	_	CD	_	_	6	NMOD	_	_
5	page-one	_	NN	_	_	6	NMOD	_	_
6	article	_	NN	_	_	1	PMOD	_	_
7	``	_	``	_	_	6	P	_	_
8	Bad	_	NNP	_	_	9	NAME	_	_
9	Blood	_	NNP	_	_	6	APPO	_	_
10	''	_	''	_	_	6	P	_	_
11	on	_	IN	_	_	6	NMOD	_	_
12	the	_	DT	_	_	14	NMOD	_	_
13	generic-drug	_	JJ	_	_	14	NMOD	_	_
14	battle	_	NN	_	_	11	PMOD	_	_
15	:	_	:	_	_	19	P	_	_
16	The	_	DT	_	_	18	NMOD	_	_
17	Epilepsy	_	NNP	_	_	18	NAME	_	_
18	Institute	_	NNP	_	_	19	SBJ	_	_
19	is	_	VBZ	_	_	0	ROOT	_	_
20	not	_	RB	_	_	19	ADV	_	_
21	just	_	RB	_	_	24	NMOD	_	_
22	a	_	DT	_	_	24	NMOD	_	_
23	patient-advocacy	_	NN	_	_	24	NMOD	_	_
24	organization	_	NN	_	_	19	PRD	_	_
25	.	_	.	_	_	19	P	_	_

1	It	_	PRP	_	_	2	SBJ	_	_
2	is	_	VBZ	_	_	0	ROOT	_	_
3	primarily	_	RB	_	_	2	ADV	_	_
4	a	_	DT	_	_	8	NMOD	_	_
5	certified	_	JJ	_	_	8	NMOD	_	_
6	outpatient	_	NN	_	_	8	NMOD	_	_
7	treatment	_	NN	_	_	8	NMOD	_	_
8	facility	_	NN	_	_	2	PRD	_	_
9	providing	_	VBG	_	_	8	APPO	_	_
10	comprehensive	_	JJ	_	_	11	NMOD	_	_
11	services	_	NNS	_	_	9	OBJ	_	_
12	to	_	TO	_	_	9	DTV	_	_
13	people	_	NNS	_	_	12	PMOD	_	_
14	with	_	IN	_	_	13	NMOD	_	_
15	epilepsy	_	NN	_	_	14	PMOD	_	_
16	and	_	CC	_	_	13	COORD	_	_
17	their	_	PRP$	_	_	18	NMOD	_	_
18	families	_	NNS	_	_	16	CONJ	_	_
19	.	_	.	_	_	2	P	_	_

1	The	_	DT	_	_	2	NMOD	_	_
2	institute	_	NN	_	_	5	NMOD	_	_
3	's	_	POS	_	_	2	SUFFIX	_	_
4	advocacy	_	NN	_	_	5	NMOD	_	_
5	efforts	_	NNS	_	_	6	SBJ	_	_
6	are	_	VBP	_	_	0	ROOT	_	_
7	based	_	VBN	_	_	6	VC	_	_
8	on	_	IN	_	_	7	ADV	_	_
9	the	_	DT	_	_	10	NMOD	_	_
10	needs	_	NNS	_	_	8	PMOD	_	_
11	of	_	IN	_	_	10	NMOD	_	_
12	the	_	DT	_	_	13	NMOD	_	_
13	population	_	NN	_	_	11	PMOD	_	_
14	it	_	PRP	_	_	15	SBJ	_	_
15	serves	_	VBZ	_	_	13	NMOD	_	_
16	and	_	CC	_	_	15	COORD	_	_
17	represents	_	VBZ	_	_	16	CONJ	_	_
18	.	_	.	_	_	6	P	_	_

1	In	_	IN	_	_	7	TMP	_	_
2	1985	_	CD	_	_	1	PMOD	_	_
3	,	_	,	_	_	7	P	_	_
4	the	_	DT	_	_	6	NMOD	_	_
5	Medical	_	NNP	_	_	6	NAME	_	_
6	Tribune	_	NNP	_	_	7	SBJ	_	_
7	reported	_	VBD	_	_	0	ROOT	_	_
8	that	_	IN	_	_	7	OBJ	_	_
9	a	_	DT	_	_	11	NMOD	_	_
10	growing	_	VBG	_	_	11	NMOD	_	_
11	number	_	NN	_	_	14	SBJ	_	_
12	of	_	IN	_	_	11	NMOD	_	_
13	critics	_	NNS	_	_	12	PMOD	_	_
14	are	_	VBP	_	_	8	SUB	_	_
15	challenging	_	VBG	_	_	14	VC	_	_
16	the	_	DT	_	_	19	NMOD	_	_
17	FDA	_	NNP	_	_	19	NMOD	_	_
18	bioequivalence-therapeutic-equivalence	_	JJ	_	_	19	NMOD	_	_
19	equation	_	NN	_	_	15	OBJ	_	_
20	.	_	.	_	_	7	P	_	_

1	``	_	``	_	_	23	P	_	_
2	They	_	PRP	_	_	3	SBJ	_	_
3	contend	_	VBP	_	_	23	OBJ	_	_
4	it	_	PRP	_	_	5	SBJ	_	_
5	is	_	VBZ	_	_	3	OBJ	_	_
6	based	_	VBN	_	_	5	VC	_	_
7	on	_	IN	_	_	6	ADV	_	_
8	an	_	DT	_	_	9	NMOD	_	_
9	assumption	_	NN	_	_	7	PMOD	_	_
10	that	_	WDT	_	_	11	SBJ	_	_
11	has	_	VBZ	_	_	9	NMOD	_	_
12	not	_	RB	_	_	11	ADV	_	_
13	yet	_	RB	_	_	11	ADV	_	_
14	been	_	VBN	_	_	11	VC	_	_
15	proven	_	VBN	_	_	14	VC	_	_
16	in	_	IN	_	_	15	LOC	_	_
17	valid	_	JJ	_	_	18	NMOD	_	_
18	tests	_	NNS	_	_	16	PMOD	_	_
19	,	_	,	_	_	23	P	_	_
20	''	_	''	_	_	23	P	_	_
21	the	_	DT	_	_	22	NMOD	_	_
22	Tribune	_	NNP	_	_	23	SBJ	_	_
23	said	_	VBD	_	_	0	ROOT	_	_
24	.	_	.	_	_	23	P	_	_

1	In	_	IN	_	_	7	TMP	_	_
2	1986	_	CD	_	_	1	PMOD	_	_
3	,	_	,	_	_	7	P	_	_
4	some	_	DT	_	_	6	NMOD	_	_
5	institute	_	NN	_	_	6	NMOD	_	_
6	patients	_	NNS	_	_	7	SBJ	_	_
7	were	_	VBD	_	_	0	ROOT	_	_
8	reporting	_	VBG	_	_	7	VC	_	_
9	breakthrough	_	NN	_	_	10	NMOD	_	_
10	seizures	_	NNS	_	_	8	OBJ	_	_
11	when	_	WRB	_	_	14	TMP	_	_
12	they	_	PRP	_	_	13	SBJ	_	_
13	were	_	VBD	_	_	8	TMP	_	_
14	switched	_	VBN	_	_	13	VC	_	_
15	from	_	IN	_	_	14	DEP	_	_
16	a	_	DT	_	_	19	NMOD	_	_
17	specific	_	JJ	_	_	19	NMOD	_	_
18	brand-name	_	JJ	_	_	19	NMOD	_	_
19	medication	_	NN	_	_	15	PMOD	_	_
20	to	_	TO	_	_	14	DEP	_	_
21	a	_	DT	_	_	23	NMOD	_	_
22	generic	_	JJ	_	_	23	NMOD	_	_
23	one	_	CD	_	_	20	PMOD	_	_
24	or	_	CC	_	_	14	COORD	_	_
25	from	_	IN	_	_	24	DEP-GAP	_	_
26	one	_	CD	_	_	28	NMOD	_	_
27	generic	_	JJ	_	_	28	NMOD	_	_
28	manufacturer	_	NN	_	_	25	PMOD	_	_
29	of	_	IN	_	_	28	NMOD	_	_
30	a	_	DT	_	_	32	NMOD	_	_
31	specific	_	JJ	_	_	32	NMOD	_	_
32	product	_	NN	_	_	29	PMOD	_	_
33	to	_	TO	_	_	24	DEP-GAP	_	_
34	another	_	DT	_	_	33	PMOD	_	_
35	.	_	.	_	_	7	P	_	_

1	In	_	IN	_	_	5	ADV	_	_
2	addition	_	NN	_	_	1	PMOD	_	_
3	,	_	,	_	_	5	P	_	_
4	neurologists	_	NNS	_	_	5	SBJ	_	_
5	were	_	VBD	_	_	0	ROOT	_	_
6	beginning	_	VBG	_	_	5	VC	_	_
7	to	_	TO	_	_	6	OPRD	_	_
8	report	_	VB	_	_	7	IM	_	_
9	these	_	DT	_	_	10	NMOD	_	_
10	observations	_	NNS	_	_	8	OBJ	_	_
11	as	_	RB	_	_	8	ADV	_	_
12	well	_	RB	_	_	11	AMOD	_	_
13	.	_	.	_	_	5	P	_	_

1	Call	_	VB	_	_	0	ROOT	_	_
2	it	_	PRP	_	_	1	OBJ	_	_
3	anecdotal	_	JJ	_	_	1	OPRD	_	_
4	if	_	IN	_	_	1	ADV	_	_
5	you	_	PRP	_	_	6	SBJ	_	_
6	will	_	MD	_	_	4	SUB	_	_
7	.	_	.	_	_	1	P	_	_

1	But	_	CC	_	_	5	DEP	_	_
2	no	_	DT	_	_	4	NMOD	_	_
3	ethical	_	JJ	_	_	4	NMOD	_	_
4	physician	_	NN	_	_	5	SBJ	_	_
5	would	_	MD	_	_	0	ROOT	_	_
6	switch	_	VB	_	_	5	VC	_	_
7	patients	_	NNS	_	_	6	OBJ	_	_
8	who	_	WP	_	_	9	SBJ	_	_
9	were	_	VBD	_	_	7	NMOD	_	_
10	doing	_	VBG	_	_	9	VC	_	_
11	well	_	RB	_	_	10	MNR	_	_
12	on	_	IN	_	_	10	ADV	_	_
13	a	_	DT	_	_	15	NMOD	_	_
14	specific	_	JJ	_	_	15	NMOD	_	_
15	medication	_	NN	_	_	12	PMOD	_	_
16	from	_	IN	_	_	15	NMOD	_	_
17	a	_	DT	_	_	19	NMOD	_	_
18	specific	_	JJ	_	_	19	NMOD	_	_
19	manufacturer	_	NN	_	_	16	PMOD	_	_
20	to	_	TO	_	_	6	PRP	_	_
21	prove	_	VB	_	_	20	IM	_	_
22	a	_	DT	_	_	23	NMOD	_	_
23	point	_	NN	_	_	21	OBJ	_	_
24	.	_	.	_	_	5	P	_	_

1	We	_	PRP	_	_	2	SBJ	_	_
2	do	_	VBP	_	_	0	ROOT	_	_
3	not	_	RB	_	_	2	ADV	_	_
4	depend	_	VB	_	_	2	VC	_	_
5	on	_	IN	_	_	4	ADV	_	_
6	pharmaceutical	_	JJ	_	_	7	NMOD	_	_
7	companies	_	NNS	_	_	5	PMOD	_	_
8	for	_	IN	_	_	4	ADV	_	_
9	our	_	PRP$	_	_	10	NMOD	_	_
10	support	_	NN	_	_	8	PMOD	_	_
11	.	_	.	_	_	2	P	_	_

1	The	_	DT	_	_	2	NMOD	_	_
2	institute	_	NN	_	_	3	SBJ	_	_
3	has	_	VBZ	_	_	0	ROOT	_	_
4	governmental	_	JJ	_	_	6	NMOD	_	_
5	service	_	NN	_	_	6	NMOD	_	_
6	contracts	_	NNS	_	_	3	OBJ	_	_
7	for	_	IN	_	_	6	NMOD	_	_
8	the	_	DT	_	_	9	NMOD	_	_
9	provision	_	NN	_	_	7	PMOD	_	_
10	of	_	IN	_	_	9	NMOD	_	_
11	direct	_	JJ	_	_	13	NMOD	_	_
12	patient	_	NN	_	_	13	NMOD	_	_
13	services	_	NNS	_	_	10	PMOD	_	_
14	;	_	:	_	_	3	P	_	_
15	collects	_	VBZ	_	_	3	COORD	_	_
16	patient	_	JJ	_	_	17	NMOD	_	_
17	fees	_	NNS	_	_	15	OBJ	_	_
18	;	_	:	_	_	15	P	_	_
19	receives	_	VBZ	_	_	15	COORD	_	_
20	money	_	NN	_	_	19	OBJ	_	_
21	through	_	IN	_	_	19	MNR	_	_
22	contributions	_	NNS	_	_	21	PMOD	_	_
23	from	_	IN	_	_	22	NMOD	_	_
24	individuals	_	NNS	_	_	23	PMOD	_	_
25	,	_	,	_	_	24	P	_	_
26	foundations	_	NNS	_	_	24	COORD	_	_
27	and	_	CC	_	_	26	COORD	_	_
28	bequests	_	NNS	_	_	27	CONJ	_	_
29	.	_	.	_	_	3	P	_	_

1	The	_	DT	_	_	2	NMOD	_	_
2	funds	_	NNS	_	_	7	SBJ	_	_
3	received	_	VBN	_	_	2	APPO	_	_
4	from	_	IN	_	_	3	ADV	_	_
5	pharmaceutical	_	JJ	_	_	6	NMOD	_	_
6	firms	_	NNS	_	_	4	PMOD	_	_
7	are	_	VBP	_	_	0	ROOT	_	_
8	used	_	VBN	_	_	7	VC	_	_
9	to	_	TO	_	_	8	OPRD	_	_
10	offset	_	VB	_	_	9	IM	_	_
11	physician	_	NN	_	_	12	NMOD	_	_
12	symposiums	_	NNS	_	_	10	OBJ	_	_
13	,	_	,	_	_	7	P	_	_
14	and	_	CC	_	_	7	COORD	_	_
15	these	_	DT	_	_	16	NMOD	_	_
16	symposiums	_	NNS	_	_	17	SBJ	_	_
17	do	_	VBP	_	_	14	CONJ	_	_
18	not	_	RB	_	_	17	ADV	_	_
19	stress	_	VB	_	_	17	VC	_	_
20	any	_	DT	_	_	22	NMOD	_	_
21	particular	_	JJ	_	_	22	NMOD	_	_
22	medication	_	NN	_	_	19	OBJ	_	_
23	or	_	CC	_	_	22	COORD	_	_
24	manufacturer	_	NN	_	_	23	CONJ	_	_
25	.	_	.	_	_	7	P	_	_

1	The	_	DT	_	_	3	NMOD	_	_
2	Epilepsy	_	NNP	_	_	3	NAME	_	_
3	Institute	_	NNP	_	_	5	NMOD	_	_
4	's	_	POS	_	_	3	SUFFIX	_	_
5	reporting	_	NN	_	_	9	SBJ	_	_
6	of	_	IN	_	_	5	NMOD	_	_
7	breakthrough	_	NN	_	_	8	NMOD	_	_
8	seizures	_	NNS	_	_	6	PMOD	_	_
9	stemmed	_	VBD	_	_	0	ROOT	_	_
10	from	_	IN	_	_	9	ADV	_	_
11	concerns	_	NNS	_	_	10	PMOD	_	_
12	about	_	IN	_	_	11	NMOD	_	_
13	the	_	DT	_	_	14	NMOD	_	_
14	people	_	NNS	_	_	12	PMOD	_	_
15	we	_	PRP	_	_	16	SBJ	_	_
16	treat	_	VBP	_	_	14	NMOD	_	_
17	and	_	CC	_	_	16	COORD	_	_
18	care	_	VBP	_	_	17	CONJ	_	_
19	about	_	IN	_	_	18	ADV	_	_
20	daily	_	RB	_	_	16	TMP	_	_
21	.	_	.	_	_	9	P	_	_

1	This	_	DT	_	_	3	SBJ	_	_
2	perhaps	_	RB	_	_	3	ADV	_	_
3	was	_	VBD	_	_	0	ROOT	_	_
4	perceived	_	VBN	_	_	3	VC	_	_
5	as	_	IN	_	_	4	ADV	_	_
6	a	_	DT	_	_	10	NMOD	_	_
7	``	_	``	_	_	10	P	_	_
8	bold	_	JJ	_	_	10	NMOD	_	_
9	''	_	''	_	_	10	P	_	_
10	stance	_	NN	_	_	5	PMOD	_	_
11	,	_	,	_	_	10	P	_	_
12	and	_	CC	_	_	10	COORD	_	_
13	thus	_	RB	_	_	12	CONJ	_	_
14	suspicious	_	JJ	_	_	13	COORD	_	_
15	.	_	.	_	_	3	P	_	_

1	But	_	CC	_	_	2	DEP	_	_
2	let	_	VB	_	_	0	ROOT	_	_
3	us	_	PRP	_	_	2	OBJ	_	_
4	not	_	RB	_	_	5	ADV	_	_
5	confuse	_	VB	_	_	2	OPRD	_	_
6	profits	_	NNS	_	_	5	OBJ	_	_
7	of	_	IN	_	_	6	NMOD	_	_
8	big	_	JJ	_	_	9	NMOD	_	_
9	business	_	NN	_	_	7	PMOD	_	_
10	masquerading	_	VBG	_	_	6	APPO	_	_
11	as	_	IN	_	_	10	ADV	_	_
12	concerns	_	NNS	_	_	11	PMOD	_	_
13	for	_	IN	_	_	12	NMOD	_	_
14	people	_	NNS	_	_	17	NMOD	_	_
15	's	_	POS	_	_	14	SUFFIX	_	_
16	health	_	NN	_	_	17	NMOD	_	_
17	care	_	NN	_	_	13	PMOD	_	_
18	or	_	CC	_	_	13	COORD	_	_
19	for	_	IN	_	_	18	CONJ	_	_
20	the	_	DT	_	_	21	NMOD	_	_
21	cost	_	NN	_	_	19	PMOD	_	_
22	.	_	.	_	_	2	P	_	_

1	For	_	IN	_	_	3	PRD	_	_
2	whom	_	WP	_	_	1	PMOD	_	_
3	is	_	VBZ	_	_	0	ROOT	_	_
4	the	_	DT	_	_	5	NMOD	_	_
5	saving	_	NN	_	_	3	SBJ	_	_
6	?	_	.	_	_	3	P	_	_

1	Surely	_	RB	_	_	3	ADV	_	_
2	not	_	RB	_	_	3	DEP	_	_
3	to	_	TO	_	_	0	ROOT	_	_
4	people	_	NNS	_	_	3	PMOD	_	_
5	with	_	IN	_	_	4	NMOD	_	_
6	epilepsy	_	NN	_	_	5	PMOD	_	_
7	who	_	WP	_	_	8	SBJ	_	_
8	depend	_	VBP	_	_	4	NMOD	_	_
9	on	_	IN	_	_	8	ADV	_	_
10	the	_	DT	_	_	12	NMOD	_	_
11	same	_	JJ	_	_	12	NMOD	_	_
12	levels	_	NNS	_	_	9	PMOD	_	_
13	of	_	IN	_	_	12	NMOD	_	_
14	medication	_	NN	_	_	13	PMOD	_	_
15	in	_	IN	_	_	12	LOC	_	_
16	their	_	PRP$	_	_	17	NMOD	_	_
17	bloodstream	_	NN	_	_	15	PMOD	_	_
18	daily	_	RB	_	_	8	TMP	_	_
19	to	_	TO	_	_	8	PRP	_	_
20	maintain	_	VB	_	_	19	IM	_	_
21	seizure	_	NN	_	_	22	NMOD	_	_
22	control	_	NN	_	_	20	OBJ	_	_
23	.	_	.	_	_	3	P	_	_

1	Reina	_	NNP	_	_	2	NAME	_	_
2	Berner	_	NNP	_	_	0	ROOT	_	_

1	Executive	_	NNP	_	_	2	NAME	_	_
2	Director	_	NNP	_	_	0	ROOT	_	_

1	Arnold	_	NNP	_	_	3	NAME	_	_
2	M.	_	NNP	_	_	3	NAME	_	_
3	Katz	_	NNP	_	_	0	ROOT	_	_

